Cargando…

Role of the multi-drug efflux systems on the baseline susceptibility to ceftazidime/avibactam and ceftolozane/tazobactam in clinical isolates of non-carbapenemase-producing carbapenem-resistant Pseudomonas aeruginosa

Carbapenem-resistant Pseudomonas aeruginosa (CRPA) is one of the pathogens that urgently needs new drugs and new alternatives for its control. The primary strategy to combat this bacterium is combining treatments of beta-lactam with a beta-lactamase inhibitor. The most used combinations against P. a...

Descripción completa

Detalles Bibliográficos
Autores principales: Contreras-Gómez, María José, Martinez, José R. W., Rivas, Lina, Riquelme-Neira, Roberto, Ugalde, Juan A., Wozniak, Aniela, García, Patricia, Munita, José M., Olivares-Pacheco, Jorge, Alcalde-Rico, Manuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9574371/
https://www.ncbi.nlm.nih.gov/pubmed/36263116
http://dx.doi.org/10.3389/fphar.2022.1007162
_version_ 1784811089892999168
author Contreras-Gómez, María José
Martinez, José R. W.
Rivas, Lina
Riquelme-Neira, Roberto
Ugalde, Juan A.
Wozniak, Aniela
García, Patricia
Munita, José M.
Olivares-Pacheco, Jorge
Alcalde-Rico, Manuel
author_facet Contreras-Gómez, María José
Martinez, José R. W.
Rivas, Lina
Riquelme-Neira, Roberto
Ugalde, Juan A.
Wozniak, Aniela
García, Patricia
Munita, José M.
Olivares-Pacheco, Jorge
Alcalde-Rico, Manuel
author_sort Contreras-Gómez, María José
collection PubMed
description Carbapenem-resistant Pseudomonas aeruginosa (CRPA) is one of the pathogens that urgently needs new drugs and new alternatives for its control. The primary strategy to combat this bacterium is combining treatments of beta-lactam with a beta-lactamase inhibitor. The most used combinations against P. aeruginosa are ceftazidime/avibactam (CZA) and ceftolozane/tazobactam (C/T). Although mechanisms leading to CZA and C/T resistance have already been described, among which are the resistance-nodulation-division (RND) efflux pumps, the role that these extrusion systems may play in CZA, and C/T baseline susceptibility of clinical isolates remains unknown. For this purpose, 161 isolates of non-carbapenemase-producing (Non-CP) CRPA were selected, and susceptibility tests to CZA and C/T were performed in the presence and absence of the RND efflux pumps inhibitor, Phenylalanine-arginine β-naphthylamide (PAβN). In the absence of PAβN, C/T showed markedly higher activity against Non-CP-CRPA isolates than observed for CZA. These results were even more evident in isolates classified as extremely-drug resistant (XDR) or with difficult-to-treat resistance (DTR), where CZA decreased its activity up to 55.2% and 20.0%, respectively, whereas C/T did it up to 82.8% (XDR), and 73.3% (DTR). The presence of PAβN showed an increase in both CZA (37.6%) and C/T (44.6%) activity, and 25.5% of Non-CP-CRPA isolates increased their susceptibility to these two combined antibiotics. However, statistical analysis showed that only the C/T susceptibility of Non-CP-CRPA isolates was significantly increased. Although the contribution of RND activity to CZA and C/T baseline susceptibility was generally low (two-fold decrease of minimal inhibitory concentrations [MIC]), a more evident contribution was observed in a non-minor proportion of the Non-CP-CRPA isolates affected by PAβN [CZA: 25.4% (15/59); C/T: 30% (21/70)]. These isolates presented significantly higher MIC values for C/T. Therefore, we conclude that RND efflux pumps are participating in the phenomenon of baseline susceptibility to CZA and, even more, to C/T. However, the genomic diversity of clinical isolates is so great that deeper analyzes are necessary to determine which elements are directly involved in this phenomenon.
format Online
Article
Text
id pubmed-9574371
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95743712022-10-18 Role of the multi-drug efflux systems on the baseline susceptibility to ceftazidime/avibactam and ceftolozane/tazobactam in clinical isolates of non-carbapenemase-producing carbapenem-resistant Pseudomonas aeruginosa Contreras-Gómez, María José Martinez, José R. W. Rivas, Lina Riquelme-Neira, Roberto Ugalde, Juan A. Wozniak, Aniela García, Patricia Munita, José M. Olivares-Pacheco, Jorge Alcalde-Rico, Manuel Front Pharmacol Pharmacology Carbapenem-resistant Pseudomonas aeruginosa (CRPA) is one of the pathogens that urgently needs new drugs and new alternatives for its control. The primary strategy to combat this bacterium is combining treatments of beta-lactam with a beta-lactamase inhibitor. The most used combinations against P. aeruginosa are ceftazidime/avibactam (CZA) and ceftolozane/tazobactam (C/T). Although mechanisms leading to CZA and C/T resistance have already been described, among which are the resistance-nodulation-division (RND) efflux pumps, the role that these extrusion systems may play in CZA, and C/T baseline susceptibility of clinical isolates remains unknown. For this purpose, 161 isolates of non-carbapenemase-producing (Non-CP) CRPA were selected, and susceptibility tests to CZA and C/T were performed in the presence and absence of the RND efflux pumps inhibitor, Phenylalanine-arginine β-naphthylamide (PAβN). In the absence of PAβN, C/T showed markedly higher activity against Non-CP-CRPA isolates than observed for CZA. These results were even more evident in isolates classified as extremely-drug resistant (XDR) or with difficult-to-treat resistance (DTR), where CZA decreased its activity up to 55.2% and 20.0%, respectively, whereas C/T did it up to 82.8% (XDR), and 73.3% (DTR). The presence of PAβN showed an increase in both CZA (37.6%) and C/T (44.6%) activity, and 25.5% of Non-CP-CRPA isolates increased their susceptibility to these two combined antibiotics. However, statistical analysis showed that only the C/T susceptibility of Non-CP-CRPA isolates was significantly increased. Although the contribution of RND activity to CZA and C/T baseline susceptibility was generally low (two-fold decrease of minimal inhibitory concentrations [MIC]), a more evident contribution was observed in a non-minor proportion of the Non-CP-CRPA isolates affected by PAβN [CZA: 25.4% (15/59); C/T: 30% (21/70)]. These isolates presented significantly higher MIC values for C/T. Therefore, we conclude that RND efflux pumps are participating in the phenomenon of baseline susceptibility to CZA and, even more, to C/T. However, the genomic diversity of clinical isolates is so great that deeper analyzes are necessary to determine which elements are directly involved in this phenomenon. Frontiers Media S.A. 2022-10-03 /pmc/articles/PMC9574371/ /pubmed/36263116 http://dx.doi.org/10.3389/fphar.2022.1007162 Text en Copyright © 2022 Contreras-Gómez, Martinez, Rivas, Riquelme-Neira, Ugalde, Wozniak, García, Munita, Olivares-Pacheco and Alcalde-Rico. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Contreras-Gómez, María José
Martinez, José R. W.
Rivas, Lina
Riquelme-Neira, Roberto
Ugalde, Juan A.
Wozniak, Aniela
García, Patricia
Munita, José M.
Olivares-Pacheco, Jorge
Alcalde-Rico, Manuel
Role of the multi-drug efflux systems on the baseline susceptibility to ceftazidime/avibactam and ceftolozane/tazobactam in clinical isolates of non-carbapenemase-producing carbapenem-resistant Pseudomonas aeruginosa
title Role of the multi-drug efflux systems on the baseline susceptibility to ceftazidime/avibactam and ceftolozane/tazobactam in clinical isolates of non-carbapenemase-producing carbapenem-resistant Pseudomonas aeruginosa
title_full Role of the multi-drug efflux systems on the baseline susceptibility to ceftazidime/avibactam and ceftolozane/tazobactam in clinical isolates of non-carbapenemase-producing carbapenem-resistant Pseudomonas aeruginosa
title_fullStr Role of the multi-drug efflux systems on the baseline susceptibility to ceftazidime/avibactam and ceftolozane/tazobactam in clinical isolates of non-carbapenemase-producing carbapenem-resistant Pseudomonas aeruginosa
title_full_unstemmed Role of the multi-drug efflux systems on the baseline susceptibility to ceftazidime/avibactam and ceftolozane/tazobactam in clinical isolates of non-carbapenemase-producing carbapenem-resistant Pseudomonas aeruginosa
title_short Role of the multi-drug efflux systems on the baseline susceptibility to ceftazidime/avibactam and ceftolozane/tazobactam in clinical isolates of non-carbapenemase-producing carbapenem-resistant Pseudomonas aeruginosa
title_sort role of the multi-drug efflux systems on the baseline susceptibility to ceftazidime/avibactam and ceftolozane/tazobactam in clinical isolates of non-carbapenemase-producing carbapenem-resistant pseudomonas aeruginosa
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9574371/
https://www.ncbi.nlm.nih.gov/pubmed/36263116
http://dx.doi.org/10.3389/fphar.2022.1007162
work_keys_str_mv AT contrerasgomezmariajose roleofthemultidrugeffluxsystemsonthebaselinesusceptibilitytoceftazidimeavibactamandceftolozanetazobactaminclinicalisolatesofnoncarbapenemaseproducingcarbapenemresistantpseudomonasaeruginosa
AT martinezjoserw roleofthemultidrugeffluxsystemsonthebaselinesusceptibilitytoceftazidimeavibactamandceftolozanetazobactaminclinicalisolatesofnoncarbapenemaseproducingcarbapenemresistantpseudomonasaeruginosa
AT rivaslina roleofthemultidrugeffluxsystemsonthebaselinesusceptibilitytoceftazidimeavibactamandceftolozanetazobactaminclinicalisolatesofnoncarbapenemaseproducingcarbapenemresistantpseudomonasaeruginosa
AT riquelmeneiraroberto roleofthemultidrugeffluxsystemsonthebaselinesusceptibilitytoceftazidimeavibactamandceftolozanetazobactaminclinicalisolatesofnoncarbapenemaseproducingcarbapenemresistantpseudomonasaeruginosa
AT ugaldejuana roleofthemultidrugeffluxsystemsonthebaselinesusceptibilitytoceftazidimeavibactamandceftolozanetazobactaminclinicalisolatesofnoncarbapenemaseproducingcarbapenemresistantpseudomonasaeruginosa
AT wozniakaniela roleofthemultidrugeffluxsystemsonthebaselinesusceptibilitytoceftazidimeavibactamandceftolozanetazobactaminclinicalisolatesofnoncarbapenemaseproducingcarbapenemresistantpseudomonasaeruginosa
AT garciapatricia roleofthemultidrugeffluxsystemsonthebaselinesusceptibilitytoceftazidimeavibactamandceftolozanetazobactaminclinicalisolatesofnoncarbapenemaseproducingcarbapenemresistantpseudomonasaeruginosa
AT munitajosem roleofthemultidrugeffluxsystemsonthebaselinesusceptibilitytoceftazidimeavibactamandceftolozanetazobactaminclinicalisolatesofnoncarbapenemaseproducingcarbapenemresistantpseudomonasaeruginosa
AT olivarespachecojorge roleofthemultidrugeffluxsystemsonthebaselinesusceptibilitytoceftazidimeavibactamandceftolozanetazobactaminclinicalisolatesofnoncarbapenemaseproducingcarbapenemresistantpseudomonasaeruginosa
AT alcaldericomanuel roleofthemultidrugeffluxsystemsonthebaselinesusceptibilitytoceftazidimeavibactamandceftolozanetazobactaminclinicalisolatesofnoncarbapenemaseproducingcarbapenemresistantpseudomonasaeruginosa